CAS Number 162652-95-1 ChemSpider 8804619 Molar mass 816.92 g/mol License data EU EMA: Javlor Pubchem 10629256 ChEMBL ID 510329 | PubChem CID 10629256 UNII 5BF646324K ATC code L01CA05 (WHO) Routes of administration Intravenous ChEBI ID 90241 | |
 | ||
AHFS/Drugs.com International Drug Names Legal status In general: ℞ (Prescription only) | ||
Vinflunine (INN, trade name Javlor) is a novel fluorinated Vinca alkaloid undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.
Contents
On November 23, 2007, Pierre Fabre and BMS announced that they are terminating their license agreement for the development of vinflunine.
As of 2016 In some countries, vinflunine is the only commercially approved agent for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase III trial), with a reported median OS of about 6 months.
Buflom dil nim sulide vinflunine retrait demand
Clinical trials
It has undergone a phase III clinical trial for advanced transitional cell carcinoma of the urothelial tract.